VIDEO: Pegcetacoplan shows continued benefit in GA, but side effects may be a concern
Click Here to Manage Email Alerts
In this video, Esther M. Bowie, MD, discusses results of the GALE study, presented at the American Academy of Ophthalmology meeting.
The open-label extension study found a 35% reduction in geographic atrophy in patients who received pegcetacoplan every month and an approximately 24% reduction in patients who received it every other month, according to Bowie, a professor of ophthalmology at Penn State Health Milton S. Hershey Medical Center.
“We’re seeing delayed or slowing progression of geographic atrophy,” she said of the results.
Some patients experienced inflammation and other side effects.
“It’s exciting that we have options for geographic atrophy, but we’re concerned about some of the side effects we’re seeing reported after in the real world,” Bowie said.
Reference:
- Heier J, et al. GALE 12-month data: First-time presentation of full cohort long-term efficacy and safety of pegcetacoplan. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts